Skip to main content
. 2016 Oct 7;43(1):84–98. doi: 10.1093/schbul/sbw133

Table 1.

Demographics

P+H+ P−H+ P+H− P−H− P
N 16 17 16 18
SCID-I Diagnosis (count) Schizoaffective disorder (9); Schizophrenia (7); past MDE (on sx onset; 3); cannabis use d/o (in remission, 4); alcohol use d/o (in remission, 4); None (12); Past MDE (4); cannabis use disorder (in remission, 2); alcohol use disorder (in remission, 1); Schizophrenia (9); schizoaffective disorder (7); cannabis use disorder (in remission, 3); alcohol use disorder (in remission, 3); cocaine use disorder (in remission, 3) None (15); past MDE (2); alcohol use disorder (in remission, 1)
Age (y) 42.31±13.76 46.8235±12.47 37.75±13.78 39.67±12.98 Hall: .075
Psych: .32
Interaction: 0.69
Sex 43.75% (7) Male; 56.25% (9) Female 23.5294% (4) Male; 76.4706% (13) Female 56.25% (9) Male; 43.75% (7) Female 44.4444% (8) Male; 55.5556% (10) Female .29
Race 68.75% (11) White, 18.75% (3) Black, 6.25% (1) Other 82.3529% (14) White, 11.7647% (2) Black, 5.8824% (1) Other 56.25% (9) White, 43.75% (7) Black, 61.1111% (11) White, 33.3333% (6) Black, 5.5556% (1) Other .21
Years of education 14.125±1.9958 15.1765±2.2146 14.6±2.8486 14.8333±2.2816 .63
Currently working 25% 82.3529% 31.25% 77.7778% .00036
Full-scale IQ (from WRAT3) 99.13±4.53 98.69±4.36 98.67±4.22 103.41±3.17 Hall: .60
Psych: .60
Interaction: .53
Antipsychotic burden (CPZ equiv mgs) 446.27±110.37 401.63±91.91 .758678

Note: SCID-I, Structured Clinical Interview for DSM-4 Axis I Disorders; CPZ equivs, chlorpromazine equivalents (mgs); WRAT3, Wide-Range Achievement Test, 3rd edition; MDE, major depressive episode. Boldface represents significant values after correction for multiple comparisons.